Strand AI

Roadmap & Position in Drug Discovery

Predicts missing biological data from routine samples to enrich sparse clinical trials.

Company Overview

Builds multimodal foundation models that predict missing biological data modalities (genomics, proteomics, spatial transcriptomics) from routine patient samples, enabling pharma and biotech companies to enrich sparse clinical trial datasets for accelerated drug discovery and biomarker identification.

What They're Building

The company's public product roadmap & what they're committed to building.

Strand AI has publicly described its multimodal foundation models for cross-modal biological data imputation, including a model that predicts spatial proteomics from routine H&E staining that beats state-of-the-art, trained in under 6 weeks at a fraction of the cost of comparable efforts. Their YC profile highlights enriching patient cohorts for clinical trials and reducing assay costs by predicting molecular profiles from routine data. They have also signaled expansion into spatial biology integration and broader disease area coverage.

Latest Intelligence

Zeitgeist tracks private signals to determine where the company is heading strategically.

Routine Samples Become Multimodal Biology

May 13, 2026

Confidence:

High

New Intel: Strand AI is predicting missing omics and spatial biology data from routine samples, including spatial proteomics from H&E stains. That could lower assay costs and enrich sparse clinical trial datasets.

Founder and Key Execs

Yue Dai, Co-Founder & CEO

Co-Founder & CEO

Oded Falik, Co-Founder & CTO

Co-Founder & CTO

Founder Force Multiplier

Strand AI combines deep expertise in multimodal biological foundation models with hands-on experience building petabyte-scale spatial biology data platforms at Enable Medicine.

Funding History

2025 | Yue Dai and Oded Falik co-found Strand AI.
Early 2026 | Accepted into Y Combinator Winter 2026 batch (~$500K).
2026 | Developing multimodal foundation models and open-source biology AI tools.
Mid-2026 | Likely seed round expected based on YC trajectory and product maturity signals.

Competitors

Multimodal Bio AI

Recursion Pharmaceuticals, Insilico Medicine, Owkin, BenevolentAI, Bioptimus

Clinical Data Platforms

Tempus AI, Cradle Bio, Enveda Biosciences

Data Annotation/Infrastructure

Scale AI, Encord

Strand AI

's Moat:

Foundation models that predict missing biological data modalities from routine samples. State-of-the-art spatial proteomics prediction validated by benchmark results. Petabyte-scale spatial biology platform experience is rare. If pharma companies adopt Strand's predictions as standard, switching means losing modality prediction capabilities that influence trial design.

How They're Leveraging AI

Multimodal foundation model imputation

Cross-Modal Biological Data Imputation: Predicts missing molecular modalities (e.g., proteomics, spatial transcriptomics) from routine clinical samples like H&E images or bulk RNA-seq, enriching sparse patient datasets for clinical trials.

LLM-RAG metadata normalization

Automated Metadata Curation and Data Harmonization: Uses large language models with retrieval-augmented generation to standardize, annotate, and harmonize heterogeneous biological metadata across clinical datasets from multiple sources and formats.

Multimodal biomarker discovery

AI-Guided Biomarker Discovery and Patient Stratification: Leverages imputed multimodal patient profiles to identify novel biomarkers and stratify patient subgroups for clinical trial design, enabling precision medicine approaches in drug development.

AI Use Overview:

Using multimodal foundation model imputation across omics, LLM-RAG metadata normalization, and multimodal biomarker discovery.

More Similar Companies

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Mango Medical

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.

Back To All Companies >